Publications and Abstracts

Select Publications

Wagner AJ, Ravi V, Riedel RF, et al. nab-Sirolimus for Patients with Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol Oct 2021; Online ahead of print

Kopparthy P, Murphy MDC. Rapid and Durable Response With Nab-Sirolimus After Everolimus Failure in a Patient With Perivascular Epithelioid Cell Tumors (PEComas) of the Uterus. Cureus 2021;13(5):e14951

Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: Final results of a phase I trial. Clin Cancer Res 2013;19(19):5474-5484

CTOS Presentations

Schulte B, Gopa I, Demeure M, et al. Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). Poster Presentation at Connective Tissue Oncology Society (CTOS) Annual Meeting November 2022 (Download Poster)

Ganjoon KN, Dickson MA, Ravi V, et al. Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa). Poster Presentation at Connective Tissue Oncology Society (CTOS) Annual Meeting November 2022 (Download Poster)

Wagner A, Ravi V, Riedel RF, et al. Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComa treated with nab-sirolimus, showing durability of response and long-term safety. Poster Presentation at Connective Tissue Oncology Society (CTOS) Annual Meeting November 2022 (Download Poster)

EORTC-NCI-AACR Presentation

Hou S, Nieva J, Desai N. KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity. Poster Presentation at EORTC-NCI-AACR Symposium October 2022, Barcelona, Spain. (Download Poster)

AMPECT Registration Study Presentations

Hou S, Du H, Schmid A, Kwiatkowski D, Desai D. nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. Poster Presentation at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 (Download Poster)

Wagner A, Ravi V, Riedel RF, Ganjoo KN, et al. Final Analysis from AMPECT, an open-label phase 2 registration trial of nab-sirolimus for patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Oral Presentation at CTOS November 2021, Virtual (Abst #108747) (Link to Summary of Data)

Wagner A, Ravi V, Ganjoo KN, Van Tine BA, et al. Long-term follow-up from AMPECT, an open-label phase 2 registration trial of nab-sirolimus for patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Oral Presentation at CTOS November 2020, Virtual (Abst #3463014)

Wagner A, Ravi V, Ganjoo KN, Van Tine BA, et al. Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT. Poster discussion at ASCO June 2020, Virtual (Abst #11516JCO 2020 38, no. 15_suppl

Dickson MA,  Ravi V, Ganjoo KN, et al. Weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): results from AMPECT, an open-label phase 2 registration trial with independent radiology review. Oral presentation at CTOS November 2019, Tokyo, Japan (Abst #3206452)

Wagner A, Dickson MA, Ravi V, et al. Mutational and biomarker correlative analysis of mTOR pathway aberrations in patients with advanced malignant perivascular epithelioid cell tumors (PEComa) treated with nab-sirolimus: results from AMPECT, an open-label phase 2 registrational trial. Poster presentation at CTOS November 2019, Tokyo, Japan (Abst #3258096)

Wagner A, Ravi V, Ganjoo KN, et al. ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase 2 Registration Trial. Oral presentation at ASCO June 2019, Chicago, IL (Abst #11005JCO 2019 37, no. 15_suppl

Select Presentations: Expanded Access Program and Other Clinical Trials

Dickson MA, Ravi V, Chen J, et al. nab-sirolimus in patients with malignant PEComa previously treated with mTOR inhibitors: Emerging experience from an expanded access program. Oral presentation at CTOS November 2021 (Abst #1080984) (Link to Summary of Data)

Dickson MA, Ravi V, Ganjoo K et al. Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations. Poster presentation at ASCO 2021, Virtual (Abst # 339405)

Simon M, Gomberg-Maitland M, Oudiz RJ, e al. Patients with severe pulmonary arterial hypertension treated with ABI-009, nab-sirolimus, an mTOR inhibitor: Interim results from a phase 1 clinical trial. Poster presentation at ACC 2019, New Orleans, LA (Abst #1242-482 * Best Poster Award* J Am Clin Cardiol 2019 Vol 73, Issue 9 Suppl 1

Simon M, Gomberg-Maitland M, Oudiz RJ, et al. ABI-009, nab-sirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension. Poster presentation at ATS 2019, Orlando, FL (Abst #A4409Am J Resp Critical Care Med 2019;199:A4409

Select Preclinical Presentations

Hou S, Du H, Schmid A, Kwiatkowski D, Desai N. nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts. Poster Presentation at AACR-NCI-EORTC 2021, Virtual International Conference on Molecular Targets and Cancer Therapeutics (P138)

Hou S, Schmid A, Desai N. ABI-009 (nab-sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors. Poster Presentation at AACR 2019, Atlanta, GA (Abst#348Cancer Res 2019, Vol 79 (13)

Hou S, Schmid A, Desai N. Distinct pharmacokinetics, tissue distribution and CNS penetration of ABI-009 (nab-sirolimus). Poster Presentation at AACR 2019, Atlanta, GA (Abst#3896Cancer Res 2019, Vol 79 (13)